Cisplatin

For research use only. Not for use in humans.

目录号:S1166 别名: cisplatinum, cis-diamminedichloroplatinum II, CDDP 中文名称:顺铂

Cisplatin Chemical Structure

CAS No. 15663-27-1

Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) 是一种无机铂络合物,在肿瘤细胞中能够通过形成DNA加合物抑制 DNA synthesis。Cisplatin 可激活ferroptosis并诱导autophagy建议现配现用。

规格 价格 库存 购买数量  
RMB 782.33 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cisplatin发表文献322篇:

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) 是一种无机铂络合物,在肿瘤细胞中能够通过形成DNA加合物抑制 DNA synthesis。Cisplatin 可激活ferroptosis并诱导autophagy建议现配现用。
特性 Cisplatin是最广泛使用的且最有力的化疗药物之一。不建议使用DMSO溶解。[7]
靶点
DNA synthesis [1]
(Tumor cells)
体外研究

Cisplatin 通过与DNA相互作用形成DNA交联剂诱导细胞毒性,激活多条信号转导通路, 包括Erk, p53, p73, 和MAPK,其中对激活凋亡影响最大。[1] Cisplatin (30 μM) 处理 HeLa 细胞6小时,显著激活Erk,持续到随后的14个小时期间。Cisplatin 还具有有效的抗肿瘤活性,诱导肿瘤细胞死亡[2]。Cisplatin可引起肾小管上皮细胞(RPTC)发生细胞凋亡,引起细胞收缩,使caspase 3活性提高50倍,磷脂酰丝氨酸外翻提高4倍,染色质凝集和DNA倍性分别提高5 和15倍。[4] Cisplatin (800 μM)处理 RPTC 4个小时,产生细胞坏死的典型特征。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Human osteosarcoma cells (HOS, 143B, U2OS and MG‑63) NXHGcGQ{S2WubDDjfYNt\SCjbnHsfZNqew>? MoPqNkDPxE1? MWS0PEBp NXvRdnlrS2m|cHzheIlvKHS{ZXH0cYVvfCCvYYLr[YRtgSCrbnPy[YF{\WRidHjlJGczN01icH;weYxifGmxbjDpckBidGxiY3XscEBtcW6ncz6= M3P2NVMyODV7MEiz
OVC cells (A2780, TOV-112D, and cis-A2780) MmOxR4VtdCCFeYTveI95cWOrdImgRZN{[Xl? NYS1XGY3OC53LDCxMEAzNjVuIEWsJFExNCB{MDygZY5lKDVyIN88US=> NH\oWFI1QCCq MkHGR49u[mmwYYTpc44hd2ZiY3nzdIxifGmwIHHu[EBOTUtiaX7obYJqfG:{IHPvZolu\XSrbnniJEgyOCCwTTmg[Y5p[W6lZYOgZ4VtdCCmZXH0bEBqdiC2aILl[UBwfmG{aXHuJINidmOncjDj[YxtKGyrbnXzJEhCOjd6MDygWG9XNTFzMlSsJIFv\CClaYOtRVI4QDBrLh?= NXS0NGw2OzFyNUe2NVE>
HCC cell lines HepG2 and Huh7 MnHnR4VtdCC4aXHibYxqfHliYYPzZZk> NFmxUW4xNTNyIN88US=> M4Hv[FQ5KGh? M3LUZWNFOTN|KzDIR2Mh[2WubIOg[ZhpcWKrdDDy[ZNqe3SjbnPlJJRwKGOrc4DsZZRqdi5? NXP6cYxYOzFyNU[1N|I>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ATF3; 

PubMed: 20651982     


ATF3 protein expression levels after treatment with low and cytotoxic doses of cisplatin (1 and 10 µg/ml) and carboplatin (27 and 270 µg/ml) in SKOV-3, MCF-7, PC3, A2780-cp, and A549 cell lines.

FEN1; 

PubMed: 29541412     


MCF-7, BT-474, and MDA-MB-231 cells were treated with increasing concentrations of cisplatin for 24 h, and FEN1 protein expression was analyzed by western blotting.

PD-L1 / p-MEK / MEK / p-STAT3 / STAT3; 

PubMed: 29228662     


Expression of PD-L1, phosphor-MEK (p-MEK), total MEK, phosphor-STAT3 (p-STAT3), and total STAT3 in HNSCC cells was measured by western blotting. Cisplatin treatment increased PD-L1 and p-MEK expression.

LC3B-I / LC3B-II / Beclin-1; 

PubMed: 26715839     


Cells seeded and treated with 2 μg/mL cisplatin for 0 hours (h) (control), 24, 48, and 72 hours, then subjected to Western blot analysis of LC3B and Beclin-1 expression. β-Actin used as loading control. Data showed LC3B-II accumulation and Beclin-1 upregulation in a time-dependent manner.

p-AMPK / AMPK / p-mTOR / mTOR; 

PubMed: 26715839     


A549 cells treated with 2 μg/mL cisplatin for 0 hours (h) (control), 24, 48, and 72 hours; protein extracts were subjected to Western blot analysis of p-AMPK, AMPK, p-mTOR, mTOR, and β-actin. 

20651982 29541412 29228662 26715839
Immunofluorescence
H2A.X / RPA; 

PubMed: 28993682     


Representative immunofluorescence of RPA and γH2A.X foci in cisplatin and/or olaparib treated cell CC cell lines along with PARP1 silenced cell treated with cisplatin.

γ-H2A.X / 53BP1; 

PubMed: 28993682     


Representative immunofluorescence of 53BP1 foci and γH2A.X foci in indicated treatment or siRNA transfection in CC cells. Cisplatin and olaparib both induce 53BP1 foci in CC cell line but combination of both drug or cisplatin treatment in PARP1 depleted cells produces higher number of 53BP1 foci and display more number of γH2A.X foci which co-localizes with each other.

N-cadherin / E-cadherin / Vimentin ; 

PubMed: 28105207     


Cell shape was observed by phase contrast microscopy and immunocytofluorescence. Staining of E-cadherin, N-cadherin and vimentin for the two groups of cells was observed by fluorescence microscope (magnification, ×400; Scale, 25 µm). Cells treated with cisplatin had higher N-cadherin expression.

LC3B; 

PubMed: 26715839     


A549 cells were treated with 4 μg/mL cisplatin for 24 hours and stained by indirect immunofluorescence for LC3B. Distribution of endogenous LC3B was reviewed and scored under fluorescent microscope.

28993682 28105207 26715839
Growth inhibition assay
Cell viability; 

PubMed: 26062553     


Quercetin enhanced cisplatin sensitivity of 143B. 143B cells were treated with cisplatin at 0, 2, 4, 6, 8, 10, and 12 μM for 24 h. Quercetin was dissolved in water with 0.5 % (v/v) ethanol. Water with 0.5 % ethanol was used for the control. 143B cells co-treated with 5 μM quercetin and 5 μM cisplatin showed a cisplatin IC50 of 4.21 μM, while an IC50 of 6.12 μM was observed in cisplatin treatment. In “Cisplatin + quercetin” group, cells were treated with 5 μM quercetin for 12 h before cisplatin treatment. 

26062553
体内研究

Cisplatin已被证实可有效作用于多种动物肿瘤模型,抑制肿瘤生长,包括头颈部肿瘤移植瘤,宫颈鳞状细胞癌移植瘤,睾丸癌移植瘤,卵巢癌移植瘤,乳腺癌移植瘤,结肠癌移植瘤,肝母细胞瘤移植瘤,等等。Cisplatin (5 mg/kg) 在实验第一天和第七天静脉注射处理浆性移植瘤Ov.Ri(C) 和 OVCAR-3,肿瘤生长抑制率 (TGI)分别为 77.5% 和85.1%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[3]

- 合并
  • Cell lines: 白血病 L1210/0 细胞
  • Concentrations: 7 μg/mL
  • Incubation Time: 2 小时
  • Method:

    L1210/0细胞培养在McCoy's 5A培养基中,培养基中补充有 15% calfserum, 和Fungizone,在 37°C下含5% CO2的培养箱中做悬浮培养,细胞呈指数生长趋势。Cisplatin (7 μg/mL) 在37°C下处理L1210/0 细胞2小时。为了测量生长抑制情况,进行细胞离心,洗涤一次,再按30 × 103 - 50 × 103 个细胞/mL的密度悬浮于新鲜培养基中,再温育3天。使用库氏计数仪测定细胞数。使用同等体积的0.4% 台酚蓝对细胞进行等分稀释。生存力表示为不含台酚蓝的细胞百分数。上述与Cisplatin温育的细胞 也稀释成0.1%琼脂,生长2周,计算菌落数。


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 60 mg/mL (199.96 mM)
DMF 12 mg/mL (39.99 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 300.05
化学式

Cl2H6N2Pt

CAS号 15663-27-1
储存条件 2年 4°C(避光) 粉末
1周 4°C(避光)溶于溶剂
别名 cisplatinum, cis-diamminedichloroplatinum II, CDDP

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the appropriate concentration of DMF for cell culture and animal study?

  • 回答:

    It depends on the cell type. The final concentration of DMF should be better limited to less than 0.1% if possible, or below 1%. Using saline as a vehicle for cisplatin at up to 3mg/ml is recommended. it's a suspension and can be administrated via oral gavage.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Cisplatin | Cisplatin ic50 | Cisplatin价格 | Cisplatin DMSO溶解度 | 采购Cisplatin | Cisplatin生产 | Cisplatin 小鼠 | Cisplatin化学结构 | Cisplatin分子量 | Cisplatin molecular weight | Cisplatin说明书 | Cisplatin供应商 | Cisplatin体内 | Cisplatin细胞系 | Cisplatin浓度 | Cisplatin nmr | Cisplatin核磁 | Cisplatin半数抑制浓度 | Cisplatin体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID